Navigation Links
invivodata Certified to Deliver EXACT in COPD Trials

PITTSBURGH, April 23 /PRNewswire/ -- invivodata inc., the industry leader in electronic Patient-Reported Outcomes (ePRO) solutions and services for global clinical research, today announced that it has completed a certification program to provide the EXAcerbations of Chronic pulmonary disease Tool (EXACT) on its DiaryPRO(C) field-based ePRO system.

The EXACT is a Patient-Reported Outcome (PRO) measure for evaluating the frequency, severity, and duration of acute exacerbations of chronic obstructive pulmonary disease (COPD) and chronic bronchitis (AECB) in international clinical trials. Developed by United BioSource Corporation's (UBC) Center for Health Outcomes Research, with significant input from clinical and instrument development experts and involvement of the U.S. Food and Drug Administration (FDA), the EXACT is the industry's only standardized tool for measuring exacerbations of COPD.

"Being a certified provider of this unique tool enables us to offer our global customers a reliable and efficient means of implementing the EXACT in their clinical trials as they develop more effective COPD treatments," said Tom Henson, invivodata vice president of marketing.

COPD, which includes chronic bronchitis and emphysema, is a disease characterized by obstruction to airflow that interferes with normal breathing. COPD is the fourth leading cause of death in the world, and further increases in the prevalence and mortality of the disease are predicted in the coming decades (Source: In the United States 11.4 million Americans are diagnosed with the disease with over 122,000 deaths each year. Clinical researchers have put significant effort into developing new COPD treatments, as evidenced by the 33% increase in clinical trials for new COPD medications since 2006 (Source:

"We are pleased to certify invivodata on the electronic delivery of the EXACT and to continue our work with them in assuring high quality data in all types of clinical studies in which the instrument is used," said Dr. Nancy Kline Leidy, senior vice president of scientific affairs for UBC and Principal Investigator of the EXACT-PRO Initiative. "We have found their e-diary device meets the needs of the EXACT and is ready for use in international trials."

Licensing agreements to use the EXACT are obtained directly from United BioSource Corporation.

About invivodata inc.

invivodata combines behavioral science, information technology, and clinical research expertise to capture high quality clinical trial data directly from patients. invivodata's electronic Patient-Reported Outcomes (ePRO) solutions, which are based on over 20 years of research, deliver reliable patient self-reported data by driving patient compliance with the protocol and eliminating recall biases that plague paper-based self-report data. invivodata's solutions include comprehensive trial-support services that facilitate the collection of ePRO data, web-based access to study data and operational reports that give researchers and sponsors visibility into study progress, and scientific and regulatory consulting on the use of PRO data in a regulated environment. invivodata's solution has been used in more than 275 clinical programs and is the industry-leading ePRO system in delivering primary efficacy data for FDA drug approvals. invivodata inc. is a privately held company with global headquarters in Pittsburgh, Pa., USA; its European headquarters is in London, England; and its technology development center is in Scotts Valley, Calif., USA. For more information visit

About United BioSource Corporation

United BioSource Corporation delivers science-based solutions to support the development and commercialization of pharmaceuticals, biotechnology, and medical devices. The company leverages a unique suite of scientific and strategic capabilities to demonstrate product effectiveness and safety, manage and minimize risk, document economic value, and secure appropriate third-party payment for prescription medicines and other medical technology. UBC's global operations are managed by research scientists and industry experts in offices throughout North America and Europe. The company is headquartered in Bethesda, Maryland. For more information, please visit

    For more information, contact:

    invivodata inc.
    Christine Tobin
    Corporate Communications Specialist
    (412) 390-3000, ext. 3502

SOURCE invivodata inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. invivodata Captures Symptom Relief Data in Endometriosis Trial
2. MedNet Solutions Certified to Score SF-12v2 Health Survey
3. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
4. Argonauta Communications Certified as Women-Owned Business by the Womens Business Enterprise National Council (WBENC)
5. Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance
6. New Study Suggests Rx Estrogen Delivery Through the Skin May Show Safety Benefits as Opposed to Oral Delivery
7. Michael J. Fox Foundation Awards $2.1 Million to Improve Drug Delivery in Parkinsons Disease
8. DSM Obtains Exclusive World-Wide License for Innovative Drug Delivery Technology
9. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
10. Reproductive Partners Participates in New IVF Progesterone Delivery System Study
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
Breaking Medicine News(10 mins):